|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, silencing MSH6 combined with DDP reduced expressions of c-myc, cyclin D1, Bcl-2, Stathmin, and PCNA, and elevated Bax expression, whereas inhibiting OS cell viability, impeding cell cycle distribution, and inducing apoptosis.
|
30456894 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> The results showed that both HDAC4 and PCNA were increased in human OS tissues.
|
31552187 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, the potential mechanism of miR-29 in OS remains largely unknown. miR-29 was highly expressed in OS and overexpression of miR-29 promoted OS cell proliferation, as well as proliferating cell nuclear antigen (PCNA) expression and migration, whereas lower expression of miR-29 inhibited OS cell proliferation, PCNA expression and migration.
|
30655843 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that CA dose-dependently inhibited cell viability and PCNA expression in osteosarcoma cells.
|
30582213 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, CCEPR is a potential prognostic predictor and functions as oncogenic long non-coding RNA (lncRNA) to regulate cell proliferation via PCNA in osteosarcoma.
|
30861164 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The meta-analysis suggested that PCNA overexpression in osteosarcoma patients is associated with low OS, but not significantly with DFS (RR = 1.82, 95% CI 1.53-2.18, P = .000; RR = 1.15, 95% CI 0.91-1.44, P = 0.234).
|
29019895 |
2017 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, GAS5 suppressed tumor volume, Ki-67 and PCNA staining, and EMT process in the development of osteosarcoma in vivo.
|
28519068 |
2017 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified 10 important pathways based on gene pairs with altered PCC > 1 in the disrupted modules (P < 0.01), and PCNA, ATP6V1C2, ATP6V1G3, FEN1, CDC7, and RPA3 (expressed in these pathways) were selected as key genes of OS.
|
27706618 |
2016 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The cell cycle‑related genes, cyclin‑dependent kinase (CDK)4 and cyclin D1 were positively correlated with SerpinE2 expression in patient‑derived tissue and in osteosarcoma cells.
|
27221371 |
2016 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of osteosarcoma cell progression by MacroH2A via the downregulation of cyclin D and cyclin‑dependent kinase genes.
|
25378143 |
2015 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
When HMGN2 expression was enhanced, the expression of cyclin D1 and PCNA was downregulated in osteosarcoma cells.
|
25530340 |
2015 |
|
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of RASSF5 markedly suppressed cell proliferation and invasion, and induced cell apoptosis in the OS cell lines with increased expression of MST1, LATS1 and p53 and decreased expression of PCNA and MMP-9.
|
25109282 |
2014 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simultaneously, Med19 downregulation decreased the expression of Ki67 and proliferating cell nuclear antigen (PCNA) in tumour samples from OS xenograft nude mice.
|
24565852 |
2014 |